(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of 36.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.25%.
Voyager Therapeutics's revenue in 2026 is $31,316,000.On average, 14 Wall Street analysts forecast VYGR's revenue for 2026 to be $3,461,327,629, with the lowest VYGR revenue forecast at $217,952,329, and the highest VYGR revenue forecast at $8,228,812,432. On average, 11 Wall Street analysts forecast VYGR's revenue for 2027 to be $4,161,054,686, with the lowest VYGR revenue forecast at $1,089,761,646, and the highest VYGR revenue forecast at $7,176,858,843.
In 2028, VYGR is forecast to generate $4,314,344,118 in revenue, with the lowest revenue forecast at $1,089,761,646 and the highest revenue forecast at $12,962,047,583.